Tagged with Medicine

Switzerland Emanuele Ostuni, CEO of ARTBIO, delves into the company’s innovative approach to radioligand therapies, focusing on its potential to replace chemotherapy and provide more effective treatment options for patients. Ostuni emphasizes the company’s commitment to precision oncology, with a strong team spread across Switzerland, Norway, USA, and the UK.  …

Global The 2024 Access to Medicine Index, released today, highlights some of the key milestones reached by global pharma in fostering access to their medicines in low- and middle-income countries (LMICs). Novartis tops the ranking – based on a wide-ranging assessment of access governance, R&D, and product delivery – meaning that…

Global Traditional drug discovery is fraught with failure and often like trying to find a needle in a haystack. Even once a candidate is identified, the development process takes thousands of man-hours and generally billions of dollars. Artificial Intelligence has the potential to change this paradigm. It can aggregate and synthesize…

Switzerland Switzerland is widely praised for its excellent universal healthcare system and strong pharma sector. Seen as a bastion of efficiency and innovation, the country is nonetheless falling behind its European counterparts when it comes to healthcare digitalisation. Recent PharmaBoardroom interviewees weigh in on the country’s digital lag, its electronic patient…

Mexico The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could be forgiven for thinking that attempting to bring innovative medicines to Mexico is a thankless task. Yet, as several country…

Mexico Jorge Luis Caridad, managing director of Johnson & Johnson Innovative Medicine, Mexico, explores his 18-year journey within the company, emphasizing his alignment with J&J’s values and its mission to transform global health. Caridad discusses the challenges and opportunities presented by the Mexican market, the company’s commitment to advancing innovation in…

Global The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez shares some exclusive insights on where pharma has made significant strides on the important metric of ‘patient reach’ and the…

Hong Kong Johnson & Johnson Innovative Medicine veteran and general manager of the company’s Hong Kong & Macau affiliate SunKeun Huh explains J&J Hong Kong’s strong position in schizophrenia and its significant oncology milestones, comments on the affiliate’s push to enhance clinical trials in alignment with mainland China, local talent development and the…

China Despite an adverse funding panorama and looming geopolitical tensions, Chinese biotech is still thriving. Companies originating in China are advancing promising pipelines, going public, looking beyond China’s borders with a record 63 cross-region out-licensing deals in 2023, and attracting the attention of global pharma. Recent PharmaBoardroom interviewees weigh in on…

Africa The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at the DIA Europe conference earlier this year. The African Medicines Agency (AMA) is paving the way for Africa to achieve…

Global The timely and equitable provision of treatment and prevention tools is just one part of the ongoing fight against HIV. Local, national, regional, and international authorities – many of which still labour under misguided preconceptions about people living with HIV – need to come together to effectively buttress the provision…

Global In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step up, and the establishment of some vital institutional structures in the first decade of the millennium, access is up, while…